<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Anim</journal-id><journal-id journal-id-type="iso-abbrev">Exp. Anim</journal-id><journal-id journal-id-type="publisher-id">EXPANIM</journal-id><journal-title-group><journal-title>Experimental Animals</journal-title></journal-title-group><issn pub-type="ppub">1341-1357</issn><issn pub-type="epub">1881-7122</issn><publisher><publisher-name>Japanese Association for Laboratory Animal Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24770651</article-id><article-id pub-id-type="pmc">4160987</article-id><article-id pub-id-type="publisher-id">13-0082</article-id><article-id pub-id-type="doi">10.1538/expanim.63.257</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Regulation of Apelin and Its Receptor Expression in Adipose Tissues of
Obesity Rats with Hypertension and Cultured 3T3-L1 Adipocytes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Hongxian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Xian Wu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Changning</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Huali</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Murohara</surname><given-names>Toyoaki</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Qiuyan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1)</label>Department of Cardiology, Shanghai First People&#x02019;s Hospital,
Shanghai Jiao Tong University, Shanghai, P.R. China</aff><aff id="aff2"><label>2)</label>Department of Cardiology, Nagoya University Graduate School
of Medicine, Nagoya, Japan</aff></contrib-group><author-notes><corresp>Address corresponding: Q. Dai, Department of Cardiology, Shanghai First People&#x02019;s
Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai 200080, P.R.
China</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>63</volume><issue>2</issue><fpage>257</fpage><lpage>267</lpage><history><date date-type="received"><day>25</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9;2014 Japanese Association for Laboratory Animal
Science</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>The apelin/APJ system has been implicated in obesity-related hypertension. We
investigated the mechanism responsible for the pathogenesis of obesity-related
hypertension with a special focus on the crosstalk between AngII/its type 1 receptor
(AT1R) signaling and apelin/APJ expression. Sprague-Dawley rats fed a high-fat
(obesity-related hypertension, OH) or normal-fat diet (NF) for 15 weeks were randomly
assigned to one of two groups and administered vehicle or perindopril for 4 weeks.
Compared to the NF rats, the OH rats showed lower levels of plasma apelin and apelin/APJ
mRNAs of perirenal adipose tissues, and these changes were restored by perindopril.
Administration of the AT1R antagonist olmesartan resulted in the restoration of the
reduction of apelin and APJ expressions induced by AngII for 48 h in 3T3-L1 adipocytes.
Among several inhibitors for extracellular signal-regulated kinases 1/2 (ERK1/2) PD98059,
p38 mitogen-activated protein kinase (p38MAPK) SB203580 and phosphatidylinositol 3-kinase
(PI3K) LY294002, the latter showed an additive effect on AngII-mediated inhibitory
effects. In addition, the levels of p-Akt, p-ERK and p38MAPK proteins were decreased by
long-term treatment with AngII (120 min), and these changes were restored by Olmesartan.
Apelin/APJ appears to be impaired in obesity-related hypertension. The AngII
inhibition-mediated beneficial effects are likely attributable, at least in part, to
restoration of p38/ERK-dependent apelin/APJ expression in diet-induced obesity-related
hypertension.</p></abstract><kwd-group><kwd>angiotensin II</kwd><kwd>apelin</kwd><kwd>hypertension</kwd><kwd>obesity</kwd><kwd>3T3-L1 adipocytes</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The incidence and prevalence of obesity and overweight, soaring at alarming rates in
industrialized countries and progressively increasing in the developing world, are pressing
global health issues [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r8" ref-type="bibr">8</xref>]. Animal and clinical studies have shown that obesity is strongly
associated with the development and aggravation of hypertension [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r28" ref-type="bibr">28</xref>, <xref rid="r34" ref-type="bibr">34</xref>], known as obesity-related
hypertension (OH). Accumulated experimental evidence points to visceral obesity as the most
important risk factor for hypertension and cardiovascular disease [<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r25" ref-type="bibr">25</xref>, <xref rid="r27" ref-type="bibr">27</xref>]. Visceral adipose tissue
is critical in the production and secretion of pathologic adipocytokines that are thought to
mediate OH, such as renin, angiotensin, aldosterone, endothelin and nonesterified fatty
acids (NEFAs) [<xref rid="r2" ref-type="bibr">2</xref>]. Changes in the types and levels of
these adipocytokines contribute to the development of hypertension [<xref rid="r2" ref-type="bibr">2</xref>].</p><p>Apelin is a bioactive peptide originally isolated in 1998 from bovine stomach extracts
[<xref rid="r30" ref-type="bibr">30</xref>]. Apelin was found to be an adipocytokine
[<xref rid="r3" ref-type="bibr">3</xref>], and it has cardioprotective properties [<xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. Apelin
exerts a potent vasodilation effect and lowers blood pressure (BP) via a nitric oxide
(NO)-dependent mechanism [<xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r31" ref-type="bibr">31</xref>], and it inhibits
angiotensin II (AngII)-mediated vasoconstriction through binding to its receptor, APJ [<xref rid="r12" ref-type="bibr">12</xref>]. The APJ receptor is a G-protein-coupled receptor
that was identified in humans in 1993 [<xref rid="r23" ref-type="bibr">23</xref>]. APJ
shares a close identity to the AngII type 1 receptor (AT1R) and named as APJ (putative
receptor protein related to AT1), but does not bind AngII. The Apelin/APJ system has been
shown to exert a potent hypotensive effect <italic>in vivo</italic> and to play a
counter-regulatory role against the pressor action of AngII [<xref rid="r14" ref-type="bibr">14</xref>]. Lower levels of plasma apelin or levels of apelin/APJ mRNAs and protein have
been observed in cardiovascular tissues in spontaneous hypertensive rats [<xref rid="r39" ref-type="bibr">39</xref>, <xref rid="r40" ref-type="bibr">40</xref>], and
essential hypertensive patients [<xref rid="r24" ref-type="bibr">24</xref>, <xref rid="r29" ref-type="bibr">29</xref>] compared to normotensive controls, indicating the
involvement of apelin in the pathophysiology of hypertension. Apelin was also implicated in
the pathogenesis of OH [<xref rid="r35" ref-type="bibr">35</xref>].</p><p>The renin-angiotensin system (RAS) is important in BP control, and the results of an animal
study suggest the activation of the systemic and adipose RAS with hypertension [<xref rid="r4" ref-type="bibr">4</xref>]. Diet-mediated regulation of AngII production-related
gene expression (including angiotensinogen and AngII-converting enzyme) in adipose tissue
has been demonstrated, with elevations in obesity and reductions in starvation [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r33" ref-type="bibr">33</xref>]. One previous study demonstrated that the cardiac
apelin mRNA is decreased in AngII-infused rats, and its restoration was achieved by
treatment with angiotensin type 1 receptor blockers (ARBs) [<xref rid="r15" ref-type="bibr">15</xref>], suggesting that the AngII/AT1R signaling pathway is involved in the
down-regulation of apelin/APJ gene expressions in the cardiovascular system.</p><p>Here, with <italic>in vivo</italic> and <italic>in vitro</italic> investigations, we
examined the mechanism responsible for the pathogenesis of diet-induced obesity-related
hypertension, with a special focus on the relationship between the AngII/AT1R signaling
pathway and apelin/APJ expression.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec><title>Reagents</title><p>AngII was purchased from Sigma-Aldrich Corporation (St. Louis, MO). Olmesartan was
donated by Daiichi Sankyo (Tokyo, Japan). Perindopril was purchased from Servier
Pharmaceutical Co. (Tianjing, China). Phosphatidylinositol 3-kinase (PI3K) LY294002,
extracellular signal-regulated kinases 1/2 (ERK1/2) PD98059, and p38 mitogen-activated
protein kinase (MAPK) SB203580 were obtained from Calbiochem, EMD Chemicals (San Diego,
CA). Primary antibodies for phospho-Akt (Ser473), Akt, phospho-ERK1/2, ERK1/2, phospho-p38
MAPK, p38 MAPK and &#x003b2;-actin were purchased from Cell Signaling Technology (Beverly,
MA).</p></sec><sec><title>Animals and treatment</title><p>Thirty-three male Sprague-Dawley rats (3 weeks of age, 37&#x02013;51 g body weight (BW); SLACCAS,
Shanghai, China) were housed in a temperature-controlled room (22 &#x000b1; 2&#x000b0;C) with a 12-h
light&#x02013;dark cycle. All experimental procedures were performed under protocols approved by
the Shanghai Jiao Tong University Ethics Committee for the use of laboratory animals,
according to the National and Institutional Guidelines for Animal Care and Use. Rats were
firstly randomly separated into two groups: the normal-fat diet group (NF group, NF diet,
containing [weight%]: 5.28% fat, 22.1% protein, 52% carbohydrates; SLACCAS, n=16) and the
high-fat diet group (OH group, HF diet, containing [weight%]: 23% fat, 21.7% protein,
39.8% carbohydrates; SLACCAS, n=17). The high-fat diet per 100 gram is made of 57.3 gram
of normal-fat rat diet, and supplemented with 20 gram lard, 10 gram sucrose, 9 gram
casein, and 2 gram maltodextrin. All animals had access to chow and water <italic>ad
libitum.</italic></p><p>Obesity-related hypertensive (OH) rats were established by raising HF-group rats to 18
weeks of age. Then, 18-week-old NF group and OH group rats were randomly assigned to one
of four groups as follows: NC (normal-fat diet group rats, n=8), NC-P (NC rats treated
with an angiotensin-converting enzyme inhibitor, ACEI, perindopril, n=8), OH
(obesity-related hypertensive rats, n=7) and OH-P (OH rats treated with perindopril, n=7).
The NC and OH groups were administered water, whereas the OH-P and NC-P groups were
administered perindopril at 1 mg/kg of BW per day, in water.</p><p>Systolic BP (SBP) was determined by using a tail-cuff pressure analysis system (BP-98A,
Softron Beijing Inc., Beijing, China). Blood pressure was measured under conscious
conditions, and the average of 3 pressure readings was recorded for each measurement.
After 4 weeks&#x02019; treatment (at the age of 22 weeks), all rats were fasted overnight and then
euthanized with an intraperitoneal injection of pentobarbital (50 mg/kg). Blood was
collected from the abdominal aorta for biological analysis. The visceral fat (perirenal,
epididymal, and mesenteric fat pads) was excised, weighed, and stored in liquid
N<sub>2</sub> for biological analysis.</p></sec><sec><title>Cell culture</title><p>Mouse 3T3-L1 cells (American Type Culture Collection, Rockville, MD) were cultured in
Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) containing 4.5 g/l glucose, 10% fetal bovine
serum (FBS), and 1% (v/v) antibiotics in a humidified atmosphere of 95% air and 5%
CO<sub>2</sub> at 37&#x000b0;C. Differentiated 3T3-L1 adipocytes were generated according to the
method of Fernandez-Galilea <italic>et al.</italic> [<xref rid="r9" ref-type="bibr">9</xref>] with a minor modification. Briefly, two days post-confluence (day 0),
preadipocytes were induced to differentiate into adipocytes by culturing them for 72 h in
DMEM containing 4.5 g/l glucose, 10% FBS, 100 U/ml of penicillin, and 100
<italic>&#x000b5;</italic>g/ml of streptomycin, 1 <italic>&#x000b5;</italic>mol/l dexamethasone, 0.5
mmol/l isobutylmethylxantine (IBMX) and 10 <italic>&#x000b5;</italic>g/ml insulin (Sigma-Aldrich).
At day 3, the cells were cultured in DMEM containing 10% FBS and insulin for another 48 h.
Then at day 5, the media were replaced with 10% FBS and antibiotics, without insulin, and
changed every 2 days up to day 9 when the cells were considered to be differentiated into
mature adipocytes. After being cultured in serum-free DMEM for 24 h, the mature 3T3-L1
adipocytes were subjected to different treatments and analyses.</p></sec><sec><title>Quantitative real-time PCR</title><p>Total RNA was extracted from perirenal fat deposits and 3T3-L1 cells according to the
Trizol Reagent procedure (Invitrogen Life Technologies, Carlsbad, CA) and was subjected to
reverse transcription with a SuperScript RT-PCR system (Invitrogen). The resulting cDNA
was subjected to quantitative real-time PCR analysis with primers specific for apelin and
APJ (<xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Primers sequences used in quantitative real-time RT-PCR (M: mouse; R:
rat)</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1">Gene</th><th rowspan="2" align="center" valign="middle" colspan="1">GenBank No.</th><th rowspan="2" align="center" valign="middle" colspan="1">Forward primer</th><th rowspan="2" align="center" valign="middle" colspan="1">Reverse primer</th><th align="center" valign="middle" rowspan="1" colspan="1">Amplicon</th></tr><tr><th align="center" rowspan="1" colspan="1">(bp)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Apelin (M)</td><td align="left" rowspan="1" colspan="1">NM_013912.3</td><td align="left" rowspan="1" colspan="1">CGAGTTGCAGCATGAATCTGAG</td><td align="left" rowspan="1" colspan="1">TGTTCCATCTGGAGGCAACATC</td><td align="center" rowspan="1" colspan="1">107</td></tr><tr><td align="left" rowspan="1" colspan="1">APJ (M)</td><td align="left" rowspan="1" colspan="1">NM_011784.3</td><td align="left" rowspan="1" colspan="1">GCATTATCGTGGTGCTTGTAGTGA</td><td align="left" rowspan="1" colspan="1">GCAAACTGCCCAGCATGTAGA</td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">18sRNA (M)</td><td align="left" rowspan="1" colspan="1">NM_011296</td><td align="left" rowspan="1" colspan="1">TTCTGGCCAACGGTCTAGACAAC</td><td align="left" rowspan="1" colspan="1">CCAGTGGTCTTGGTGTGCTGA</td><td align="center" rowspan="1" colspan="1">127</td></tr><tr><td align="left" rowspan="1" colspan="1">Apelin (R)</td><td align="left" rowspan="1" colspan="1">NM_031612.2</td><td align="left" rowspan="1" colspan="1">CAGGCCTATTCCCAGGCTCA</td><td align="left" rowspan="1" colspan="1">CAAGATCAAGGGCCCAGTCAA</td><td align="center" rowspan="1" colspan="1">116</td></tr><tr><td align="left" rowspan="1" colspan="1">APJ (R)</td><td align="left" rowspan="1" colspan="1">NM_031349.2 </td><td align="left" rowspan="1" colspan="1">CCTGGCTTGATGCAGTTGGA</td><td align="left" rowspan="1" colspan="1">TCTGGCCTGAGACATGCAGAG</td><td align="center" rowspan="1" colspan="1">126</td></tr><tr><td align="left" rowspan="1" colspan="1">18sRNA (R)</td><td align="left" rowspan="1" colspan="1">NM_213557</td><td align="left" rowspan="1" colspan="1">AAGTTTCAGCACATCCTGCGAGTA</td><td align="left" rowspan="1" colspan="1">TTGGTGAGGTCAATGTCTGCTTTC</td><td align="center" rowspan="1" colspan="1">140</td></tr></tbody></table></table-wrap>) and with the use of a Bio-Rad CFX96<sup>TM</sup> Real-Time PCR Detection
System and Power SYBR<sup>&#x000ae;</sup> Green PCR Master Mix (Applied Biosystems, Foster City,
CA) as described [<xref rid="r6" ref-type="bibr">6</xref>]. Changes in gene expression
were normalized to 18sRNA and calculated by the 2<sup>&#x02013;&#x00394;&#x00394;Ct</sup> method. All samples were
analyzed in triplicate.</p></sec><sec><title>Western blot analysis</title><p>Total extracted protein was separated with 10% SDS-PAGE and then transferred to a
polyvinylidene difluoride membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK ).
Nonspecific binding was blocked with 5% skim milk/Tris-buffered saline with Tween for 1 h
at room temperature and then incubated with primary antibodies (diluted 1:1,000) at 4&#x000b0;C
overnight. &#x003b2;-actin was loaded as control. The band intensity was analyzed by densitometry
using Image J software.</p></sec><sec><title>Apelin and angiotensin II assay</title><p>Cell-cultured supernatants and plasma levels of apelin were quantified with apelin-12 EIA
Kits (Phoenix Pharmaceuticals, Burlingame, CA) following the manufacturer&#x02019;s instructions.
Plasma AngII was measured with a commercially available radioimmunoassay kit (BNIBT,
Beijing, China).</p></sec><sec><title>Statistical analysis</title><p>Data are expressed as mean &#x000b1; S.D. Student&#x02019;s <italic>t</italic>-test (for comparisons of
two groups) or one-way ANOVA (for comparisons of &#x02265;3 groups) followed by Bonferroni post
hoc tests were used for the statistical analyses. For the animal study, an ANOVA of
repeated measurement data was used for the comparison of the two means of BW and BP
between the NF and HF groups. Pearson&#x02019;s correlation analysis was performed to screen
potential associations among variables. All statistical analyses were performed using SPSS
software version 16.0 (SPSS Inc., Chicago, IL). A <italic>P</italic>-value&#x0003c;0.05 was
considered significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Obesity-related hypertensive (OH) rats were established</title><p>At the age of 18 weeks, the rats fed the HF diet showed much higher BW and SBP levels
compared to the control rats fed the normal diet (BW: 660.8 &#x000b1; 54.3 vs. 567.1 &#x000b1; 14.9 g;
SBP: 152.7 &#x000b1; 8.7 vs. 132.5 &#x000b1; 3.2 mmHg, respectively; <italic>P</italic>&#x0003c;0.01). Any
reading of SBP higher than 140 mmHg was considered hypertension. In this study, 3 of 17
rats fed the high-fat diet did not develop hypertension. These three rats were then
removed from the OH group.</p></sec><sec><title>Effects of perindopril on apelin and APJ expression in OH rats</title><p>At the age of 22 weeks, the OH rats still showed not only higher BW and SBP values, but
also more visceral fat (including perirenal fat, Epididymal fat, mesenteric fat, total
visceral fat weight and total visceral fat/BW) compared to the NC rats
(<italic>P</italic>&#x0003c;0.01; <xref rid="tbl_002" ref-type="table">Table
2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Characteristics of the NC, NC-P, OH, and OH-P rats after 4 weeks of perindopril
treatment</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">NC</th><th align="center" rowspan="1" colspan="1">NC-P</th><th align="center" rowspan="1" colspan="1">OH</th><th align="center" rowspan="1" colspan="1">OH-P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Body weight (g)</td><td align="center" rowspan="1" colspan="1">627.4&#x000a0;&#x000b1;&#x000a0;20.7</td><td align="center" rowspan="1" colspan="1">612.5&#x000a0;&#x000b1;&#x000a0;15.5</td><td align="center" rowspan="1" colspan="1">731.9&#x000a0;&#x000b1;&#x000a0;30.3<sup>**</sup></td><td align="center" rowspan="1" colspan="1">690.0&#x000a0;&#x000b1;&#x000a0;17.6<sup>##</sup>&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td align="center" rowspan="1" colspan="1">137.0&#x000a0;&#x000b1;&#x000a0;4.2</td><td align="center" rowspan="1" colspan="1">106.6&#x000a0;&#x000b1;&#x000a0;8.9<sup>**</sup></td><td align="center" rowspan="1" colspan="1">160.6&#x000a0;&#x000b1;&#x000a0;7.2<sup>**</sup></td><td align="center" rowspan="1" colspan="1">98.2&#x000a0;&#x000b1;&#x000a0;6.8<sup>##</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="center" rowspan="1" colspan="1">386 &#x000b1; 38</td><td align="center" rowspan="1" colspan="1">375 &#x000b1; 40</td><td align="center" rowspan="1" colspan="1">393 &#x000b1; 31</td><td align="center" rowspan="1" colspan="1">371 &#x000b1; 46</td></tr><tr><td align="left" rowspan="1" colspan="1">Perirenal fat (g)</td><td align="center" rowspan="1" colspan="1">9.0&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" rowspan="1" colspan="1">8.9&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" rowspan="1" colspan="1">12.9&#x000a0;&#x000b1;&#x000a0;1.7<sup>**</sup></td><td align="center" rowspan="1" colspan="1">11.0&#x000a0;&#x000b1;&#x000a0;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Epididymal fat (g)</td><td align="center" rowspan="1" colspan="1">6.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">6.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">30.3&#x000a0;&#x000b1;&#x000a0;3.2<sup>**</sup></td><td align="center" rowspan="1" colspan="1">27.1&#x000a0;&#x000b1;&#x000a0;1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Mesenteric&#x000a0;fat (g)</td><td align="center" rowspan="1" colspan="1">4.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">4.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">8.9&#x000a0;&#x000b1;&#x000a0;1.2<sup>**</sup></td><td align="center" rowspan="1" colspan="1">7.7&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Total visceral fat (g)</td><td align="center" rowspan="1" colspan="1">20.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="center" rowspan="1" colspan="1">20.6&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="center" rowspan="1" colspan="1">52.1&#x000a0;&#x000b1;&#x000a0;3.9<sup>**</sup></td><td align="center" rowspan="1" colspan="1">45.9&#x000a0;&#x000b1;&#x000a0;2.4<sup>#</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Visceral&#x000a0;fat/BW</td><td align="center" rowspan="1" colspan="1">0.033&#x000a0;&#x000b1;&#x000a0;0.001</td><td align="center" rowspan="1" colspan="1">0.034&#x000a0;&#x000b1;&#x000a0;0.002</td><td align="center" rowspan="1" colspan="1">0.071&#x000a0;&#x000b1;&#x000a0;0.005<sup>**</sup></td><td align="center" rowspan="1" colspan="1">0.067&#x000a0;&#x000b1;&#x000a0;0.002</td></tr></tbody></table><table-wrap-foot><p>NC: normal control, n=8; NC-P: normal control rats treated with perindopril, n=8;
OH: obesity-related hypertensive rats, n=7; OH-P: obesity-related hypertensive rats
treated with perindopril, n=7. Data are mean &#x000b1; S.D. ** <italic>P</italic>&#x0003c;0.01
vs. NC; <sup>#</sup><italic>P</italic> &#x0003c;0.05, <sup>## </sup><italic>P</italic>
&#x0003c;0.01 vs. OH.</p></table-wrap-foot></table-wrap>). Perindopril significantly reduced the BW, BP and total visceral fat in the
OH rats compared to the untreated OH rats (<italic>P</italic>&#x0003c;0.05 or
<italic>P</italic>&#x0003c;0.01). There was no significant difference in heart rate among the
four experimental groups (<xref rid="tbl_002" ref-type="table">Table 2</xref>).</p><p>The OH rats had significantly higher plasma AngII levels than the NC rats
(<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="fig_001">Fig. 1A</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Effects of perindopril on the levels of plasma AngII (A) and plasma apelin (B), and
apelin (C) and APJ (D) mRNAs expression in adipose tissue of OH rats. The plasma
AngII levels were measured by RIA and plasma apelin by ELISA analysis. C and D,
quantitative real-time PCR was used to detect apelin/APJ mRNAs of perirenal adipose
tissue. NC: normal control rats, n=8; NC-P: normal control rats treated with
perindopril, <italic>n</italic>=8; OH: obesity-related hypertensive rats, n=7; OH-P:
obesity-related hypertensive rats treated with perindopril, n=7. Data are mean &#x000b1;
S.D. of two replicates. **<italic>P</italic>&#x0003c;0.01 vs. NC;
<sup>#</sup><italic>P</italic>&#x0003c;0.05, <sup>##</sup><italic>P</italic>&#x0003c;0.01
vs. OH.</p></caption><graphic xlink:href="expanim-63-257-g001"/></fig>). The levels of plasma AngII were dramatically decreased in both the NC-P and OH-P
groups compared to the respective control groups (NC and OH rats;
<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="fig_001">Fig. 1A</xref>). Compared
to the NC rats, the OH rats had lower levels of plasma apelin and apelin/APJ mRNAs of
perirenal adipose tissues, and these changes were restored by perindopril treatment
(<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01; <xref ref-type="fig" rid="fig_001">Fig. 1B, C, D</xref>). However, perindopril showed no effect on these
parameters in the NC rats. The Pearson correlation analysis showed that the levels of
plasma apelin were negatively correlated with BW, BP and plasma AngII (r=&#x02212;0.852, &#x02212;0.498,
&#x02212;0.62, respectively; <italic>P</italic>&#x0003c;0.01) and were positively correlated with the
apelin mRNA levels of the perirenal fat tissue (r=0.761, <italic>P</italic>&#x0003c;0.01).</p></sec><sec><title>Effects of olmesartan on AngII-induced apelin and APJ expressions in cultured 3T3-L1
adipocytes</title><p>The quantitative PCR revealed that AngII treatment for 48 h reduced the levels of apelin
and APJ mRNAs of cultured 3T3-L1 adipocytes in a dose-dependent manner
(<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="fig_002">Fig. 2A</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p>Effects of olmesartan on AngII-induced apelin and APJ expressions in cultured
3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were subjected to serum-free
culture for 24 h before treatments. (A) Real-time PCR showed apelin/APJ mRNAs levels
of the 3T3-L1 adipocytes incubated with AngII at indicated concentrations for 48 h.
(B) ELISA showed the levels of apelin protein in the cultured medium of 3T3-L1
adipocytes treated with AngII (1&#x000a0;<italic>&#x000b5;</italic>mol/l) in the absence (&#x02212;) or
presence of olmesartan (1 or 10&#x000a0;<italic>&#x000b5;</italic>mol/l) for 48 h. Results are the means &#x000b1; S.D. of three or more
independent experiments. * <italic>P&#x0003c;</italic>0.05, ** <italic>P&#x0003c;</italic>0.01
vs. corresponding controls. <sup>#</sup><italic>P&#x0003c;</italic>0.05,
<sup>##</sup><italic>P&#x0003c;</italic>0.01 vs. AngII (1&#x000a0;<italic>&#x000b5;</italic>mol/l). Cont: control; AngII: angiotensin II; Olm: olmesartan;
<italic>&#x000b5;</italic>M: <italic>&#x000b5;</italic>mol/l.</p></caption><graphic xlink:href="expanim-63-257-g002"/></fig>). ELISA showed that the level of apelin protein was reduced in the condition medium
of 3T3-L1 cells treated with AngII for 48h, and this change was restored by olmesartan
treatment (1 or 10 <italic>&#x000b5;</italic>mol/l, <italic>P</italic>&#x0003c;0.05 or
<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="fig_002">Fig. 2B</xref>). Next, we
tested several signaling pathway inhibitors including PI3K inhibitor LY294002 (10
<italic>&#x000b5;</italic>mol/l), ERK1/2 inhibitor PD98059 (10&#x000a0;<italic>&#x000b5;</italic>mol/l), and
p38MAPK inhibitor SB203580 (10&#x000a0;<italic>&#x000b5;</italic>mol/l) in the presence and absence of
AngII (1&#x000a0;<italic>&#x000b5;</italic>mol/l) for 48 h. As shown in the <xref ref-type="fig" rid="fig_003">Figure 3</xref><fig orientation="portrait" fig-type="figure" id="fig_003" position="float"><label>Fig. 3.</label><caption><p>Effects of several signaling pathway inhibitors on AngII-mediated apelin/APJ mRNA
expression in cultured 3T3-L1 adipocytes. Following culture in serum-free for 24 h,
the differentiated 3T3-L1 adipocytes were treated with AngII
(1&#x000a0;<italic>&#x000b5;</italic>mol/l) in the absence (&#x02212;) or presence (+) of several signaling
pathway inhibitors (olmesartan to AT1R, LY294002 to PI3K, PD98059 to ERK1/2, and
SB203580 to p38MAPK, each at 10&#x000a0;<italic>&#x000b5;</italic>mol/l, added 30 min before AngII
treatment) for 48 h. Quantitative real-time PCR was used to detect apelin/APJ mRNAs
levels. Results are the means &#x000b1; S.D. of four or more independent experiments
performed in triplicate. * <italic>P&#x0003c;</italic>0.05, ** <italic>P&#x0003c;</italic>0.01
vs. control. <sup>#</sup><italic>P&#x0003c;</italic>0.05,
<sup>##</sup><italic>P&#x0003c;</italic>0.01 vs. AngII (1&#x000a0;<italic>&#x000b5;</italic>mol/l).</p></caption><graphic xlink:href="expanim-63-257-g003"/></fig>, pretreatment with the AT1R antagonist olmesartan (10 <italic>&#x000b5;</italic>mol/l)
diminished the inhibitory effect of AngII (1 <italic>&#x000b5;</italic>mol/l) on apelin/APJ mRNAs
expressions (<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01). Even though at the
basal condition, SB203580 and PD98059 had a comparable inhibitory effect on both gene
expressions, neither PD98059 nor SB203580 had an additive effect on the gene expressions
in the presence of AngII. LY294002 almost completely suppressed the apelin mRNA
expression, not only in absence but also in the presence of AngII, by 80%.</p></sec><sec><title>Effects of olmesartan on AngII-mediated phosphorylation of Akt, ERK1/2 and p38MAPK in
cultured 3T3-L1 adipocytes</title><p>We first examined AngII-mediated time-dependent effects on the phosphorylation of Akt,
ERK1/2 and p38MAPK. The quantitative Western blotting analysis revealed that 1
<italic>&#x000b5;</italic>mol/l of AngII increased the levels of p-Akt, p-ERK1/2 and p-p38MAPK
in a time-dependent manner (<xref ref-type="fig" rid="fig_004">Fig. 4</xref><fig orientation="portrait" fig-type="figure" id="fig_004" position="float"><label>Fig. 4.</label><caption><p>Effects of AngII on the phosphorylation of Akt, ERK1/2 and p38MAPK in cultured
3T3-L1 adipocytes. A, B and C, Representative images of Western blots (A) combined
with quantitative data of the levels of p-Akt (Ser-473), p-ERK1/2, and p-p38MAPK (B
and C) induced by AngII (1 <italic>&#x000b5;</italic>mol/l) at indicated time points.
Results are the means &#x000b1; S.D. of three independent experiments. *
<italic>P&#x0003c;</italic>0.05, ** <italic>P&#x0003c;</italic>0.01 vs. corresponding
controls.</p></caption><graphic xlink:href="expanim-63-257-g004"/></fig>). The level of p-Akt (Ser-473) reached a peak at 60 min after AngII treatment, and
the levels of both p-ERK1/2 and p-p38MAPK reached a peak at 30 min.</p><p>To further explore the potential role of olmesartan on AngII-mediated phosphorylation of
Akt, ERK1/2 and p38MAPK in adipocytes, following pretreatment with olmesartan for 30 min,
we then treated the adipocytes with AngII for a long term (120 min) for analysis. As
expected, we found that the levels of p-Akt, p-ERK and p38MAPK were reduced by the
long-term AngII treatment, and that these levels were restored by olmesartan (10
<italic>&#x000b5;</italic>mol/l; <italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="fig_005">Fig. 5</xref><fig orientation="portrait" fig-type="figure" id="fig_005" position="float"><label>Fig. 5.</label><caption><p>Effects of olmesartan on the phosphorylation of Akt, ERK1/2 and p38MAPK in response
to long-term AngII treatment in cultured 3T3-L adipocytes. After pretreatment with
or without olmesartan (10 <italic>&#x000b5;</italic>mol/l) for 30 min, the cells were
incubated with AngII (1 <italic>&#x000b5;</italic>mol/l) for an additional 120 min. A and B,
Representative images of Western blots (A) and combined with quantitative levels of
p-Akt (Ser-473), p-ERK1/2 and p-p38MAPK (B). Results are the means &#x000b1; S.D. of three
independent experiments. * <italic>P</italic>&#x0003c;0.05, ** <italic>P</italic>&#x0003c;0.01
vs. corresponding controls; <sup>#</sup><italic>P</italic>&#x0003c;0.05,
<sup>##</sup><italic>P</italic>&#x0003c;0.01 vs. AngII (1 <italic>&#x000b5;</italic>mol/l).</p></caption><graphic xlink:href="expanim-63-257-g005"/></fig>).</p></sec><sec><title>Effect of AngII on the apelin secretion in cultured 3T3-L1 adipocytes</title><p>Lastly, we performed apelin ELISAs to examine the effect of AngII on apelin secretion in
3T3-L1 adipocytes (<xref ref-type="fig" rid="fig_006">Fig. 6</xref><fig orientation="portrait" fig-type="figure" id="fig_006" position="float"><label>Fig. 6.</label><caption><p>Treatment with AngII for 1 h stimulated apelin secretion via a vesicle-releasing
pathway. 3T3-L1 adipocytes were cultured serum-free for 24 h, and then treated with
AngII (1 <italic>&#x000b5;</italic>mol/l) for 1 h with (+) or without (&#x02212;) pretreatment with
the Golgi inhibitor Brefeldin A (5 <italic>&#x000b5;</italic>g/ml), or LY294002 (10
<italic>&#x000b5;</italic>mol/l) for 30 min. The apelin secretion in cultured media was
detected by ELISA. Results are the means &#x000b1; S.D. of three or four independent
experiments. * <italic>P&#x0003c;</italic>0.05, ** <italic>P&#x0003c;</italic>0.01 vs.
control. <sup>##</sup><italic>P</italic>&#x0003c;0.01 vs. the AngII group.</p></caption><graphic xlink:href="expanim-63-257-g006"/></fig>). Interestingly, AngII (1 <italic>&#x000b5;</italic>mol/l) treatment for 1 h increased the
levels of apelin in the cultured media compared to the control group
(<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="fig_006">Fig. 6</xref>). Brefeldin
A (a Golgi inhibitor, 5 <italic>&#x000b5;</italic>g/ml) significantly reduced the basal secretion
of apelin (<italic>P</italic>&#x0003c;0.05), whereas LY294002 (10 <italic>&#x000b5;</italic>mol/l) had
no significant effect on apelin secretion. In addition, pretreatment with Brefeldin A or
LY294002 did not change the AngII-induced increase in apelin secretion in the media.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Several important observations can be made on the basis of the present study&#x02019;s results.
First, the levels of plasma apelin and apelin/APJ mRNAs of perirenal adipose tissue were
reduced in obesity-related hypertensive rats fed a high-fat diet, and these changes were
restored by AngII inhibition with ACE inhibitor treatment with perindopril. Second,
long-term treatment with AngII down-regulates Apelin and APJ expressions through the
inhibition of the p38/ERK signaling pathway in cultured 3T3-L1 cells, and this effect was
also restored by AT1R antagonism with olmesartan. The supposed mechanisms underlying the
chronic effect of AngII on apelin expression in adipose tissue are schematically represented
in <xref ref-type="fig" rid="fig_007">Fig. 7</xref><fig orientation="portrait" fig-type="figure" id="fig_007" position="float"><label>Fig. 7.</label><caption><p>Proposed mechanism of chronic inhibitory effect of AngII on apelin expression in
adipose tissue.</p></caption><graphic xlink:href="expanim-63-257-g007"/></fig>.</p><p>Previous studies indicate that visceral adipose tissue is critical in the production of
pathologic adipocytokines, and changes in the types and levels of adipocytokines lead to the
development of hypertension [<xref rid="r2" ref-type="bibr">2</xref>]. The ability of
diet-induced obesity to decrease plasma or/and adipose tissue apelin/APJ levels is likely to
contribute to the development of hypertension under experimental conditions. Here, we
observed that the levels of both plasma apelin and apelin/APJ mRNAs of perirenal adipose
tissue were significantly reduced in the OH rats. Our observations reveal that the levels of
plasma apelin were negatively correlated with BW and SBP, and positively correlated with the
apelin mRNA levels of perirenal fat tissue. It was reported that circulating apelin levels
were decreased in patients with essential hypertension [<xref rid="r24" ref-type="bibr">24</xref>, <xref rid="r29" ref-type="bibr">29</xref>]. Because the apelin/APJ system
exerts potent vasodilation, we propose that diet-induced OH may be due to the impairment of
systemic and adipose tissue apelin/APJ-mediated hypotensive action. It should be noted that
the data from a few clinical studies showed an increase in circulating apelin in obese
patients compared to normal-weight controls [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r13" ref-type="bibr">13</xref>]. This discrepancy between previous clinical studies
and the present animal study might be attributable to differences in obesity stages or to
obesity with complications such as hypertension and heart failure. This notion was supported
by a 2011 finding from the Przewlocka-Kosmala group that obese patients with hypertension
and heart failure had lower levels of plasma apelin compared to control patients [<xref rid="r24" ref-type="bibr">24</xref>]. Further studies are necessary to investigate this
issue.</p><p>Accumulating evidence shows an activation of the systemic and local adipose RAS in animals
with obesity and hypertension [<xref rid="r4" ref-type="bibr">4</xref>]. Animal and human
adipose tissues have been shown to possess all of the components necessary for the
production of AngII, including angiotensinogen, renin-like activity, and ACE [<xref rid="r4" ref-type="bibr">4</xref>]. In the present study, obesity increased the plasma
AngII concentration, and the ability of obesity to induce hypertension was abrogated by ACE
inhibitor treatment. AngII inhibition also showed an improvement of decreased plasma apelin
levels and the apelin-APJ gene expressions in local adipose tissue. We further demonstrated
that AT1R antagonism restored the AngII-induced down-regulation of apelin-APJ gene
expressions in cultured 3T3-L1 cells. Thus, diet-induced obesity appears to impair the
apelin/APJ-mediated vascular beneficial effect through its ability to activate systemic and
local adipose tissue RAS. It was reported that AngII-infusion decreased apelin mRNA
expression in the cardiac tissue, and this change was restored by olmesartan [<xref rid="r15" ref-type="bibr">15</xref>]. Taken together, these findings suggest that AngII
inhibition-mediated beneficial effects are likely attributable, at least in part, to
improvement of the impaired apelin/APJ system associated with an activation of systemic
or/and adipose tissue RAS in diet-induced OH.</p><p>The PI3K/Akt signaling pathway was reported to be involved in apelin synthesis and/or
secretion in 3T3-L1 adipocytes [<xref rid="r21" ref-type="bibr">21</xref>]. The direct
stimulation of apelin by insulin is clearly associated with the activation of PI3K/Akt and
MAPK pathways [<xref rid="r3" ref-type="bibr">3</xref>]. The signaling pathways of
inflammatory cytokine for the induction of apelin were dependent on PI3K, JNK and MAPK but
not protein kinase C activation in 3T3F442A adipocytes [<xref rid="r7" ref-type="bibr">7</xref>]. Iwanaga <italic>et al.</italic> reported that the apelin/APJ gene levels were
decreased by AngII-infusion in hypertrophied and failing hearts of rats, and the changes
were improved by AT1R antagonism [<xref rid="r15" ref-type="bibr">15</xref>]. Here we
observed that olmesartan prevented the AngII-mediated down-regulation of apelin/APJ
expressions in cultured 3T3-L1 adipocytes. Furthermore, olmesartan improved the long-term
AngII intervention (120 min)-mediated reduction of the p-ERK1/2 and p-p38MAPK levels in
adipocytes (<xref ref-type="fig" rid="fig_005">Fig. 5</xref>). These findings suggest that
the signaling pathways of AngII for the down-regulation of apelin/APJ gene expressions may
be dependent on down-regulated p38/ERK1/2 signaling pathways in adipose tissue and
adipocytes. This conception was further supported by observation that both p38MAPK inhibitor
SB203580 and ERK1/2 inhibitor PD98059 had no additive effects on apelin/APJ gene expressions
suppressed by AngII treatment alone. It should be noted that olmesartan also improved the
long-term AngII treatment (120 min)-mediated reduction of the p-Akt levels in adipocytes.
Taken together with the observation that AngII-mediated inhibitory effect on apelin-APJ
expression was significantly higher in the presence of the PI3K inhibitor than in the
presence of the p38 or ERK1/2 inhibitor, these findings suggest that there are
p38/ERK1/2-dependent and -independent signaling pathways in apelin/APJ expression in
adipocytes.</p><p>Some adipocytokines have been shown to be synthesized and stored in secretory vesicles in
adipocytes, including adiponectin, leptin and resistin [<xref rid="r37" ref-type="bibr">37</xref>, <xref rid="r38" ref-type="bibr">38</xref>]. Our present study revealed that
short-term treatment with AngII for 1 h increased the levels of apelin in the cultured
media, raising the possibility that apelin is secreted from a pre-existing pool present in
mature adipocytes in the acute response to AngII (<xref ref-type="fig" rid="fig_006">Fig.
6</xref>), although we had no related direct evidence. This notion was further supported
by the recent findings of Than <italic>et al.</italic> that AngII (1<italic>&#x000b5;</italic>mol/l
or 10 <italic>&#x000b5;</italic>mol/l) stimulated acute apelin secretion at 30 min and 2 h [<xref rid="r32" ref-type="bibr">32</xref>]. There are two secretory pathways for proteins
secreted from the cytosol to the extracellular space, including a constitutive secretory
pathway and a regulated secretory pathway [<xref rid="r19" ref-type="bibr">19</xref>]. The
Golgi inhibitor Brefeldin A decreased the basal secretion of apelin, indicating that the
Golgi system might be involved in the constitutive secretion of apelin in adipocytes. There
is a storage form of apelin in cardiomyocytes [<xref rid="r26" ref-type="bibr">26</xref>].
Based on these findings, we favor the hypothesis that short-term treatment with AngII may
trigger apelin secretion via a regulated vesicle-releasing pathway. This was further
supported by our observation that pretreatment with Brefeldin A had no effect on the
AngII-induced secretion of apelin in adipocytes. Furthermore, we found that pretreatment
with LY294002 did not affect the apelin secretion in response to the short-term AngII
treatment. Recently, a single study has reported that AngII stimulated acute apelin
secretion through MAPK/ERK pathway [<xref rid="r32" ref-type="bibr">32</xref>]. Since the
short-term treatment with AngII promoted the phosphorylation of p38MAPK and ERK1/2 in
cultured 3T3-L1 cells (<xref ref-type="fig" rid="fig_004">Fig. 4</xref>), it is possible to
speculate that the signaling pathway of the AngII-mediated acute action for the induction of
apelin secretion might be dependent on an ERK1/2 signaling pathway but not a PI3K/Akt
pathway.</p><p>The apelin/APJ system was demonstrated to exert a potent hypotensive effect [<xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r31" ref-type="bibr">31</xref>]. Our
present findings provide evidence that there is cross-talk between AngII/AT1R signaling and
the apelin/APJ system in 3T3-L1 adipocytes. The AngII inhibition-mediated beneficial effects
are likely attributable, at least in part, to restoration of the impaired apelin/APJ system
in diet-induced OH. Thus, our results provide new evidence for the benefits of RAS
inhibitors in the treatment of hypertension with obesity.</p><sec><title>Limitation</title><p>Several limitations of the present study should be pointed out. First, the sample size of
animals for each experimental group was small. Second, the calculation of the food intake
was not designed into this study protocol. Although a treatment with ACE inhibitor for a
short period of time (around 4 weeks) does not affect a food intake in rodents fed a
normal-fat or high-fat diet in some studies [<xref rid="r22" ref-type="bibr">22</xref>,
<xref rid="r36" ref-type="bibr">36</xref>], the effect of perindopril on the food intake
in this experiment will be needed to investigate in future. Third, different angiotensin
inhibitors were applied to <italic>in vivo </italic>(perindopril, ACE inhibitor) and
<italic>in vitro</italic> study (olmesartan, ARB). As known, ACE inhibitor has been
shown to be not quite suitable for cell experiments. Here, we have used an AT1R antagonist
olmesartan in 3T3-L1 cell experiments. Forth, with the exception of the perirenal fat,
other visceral fats including epididymal and mesenteric fat pads were not studied for
targeted gene expressions. Further investigation will be needed to study this issue.
Fifth, since the concentration of angiotensin II in culture experiments
(1<italic>&#x000b5;</italic>mol/l) was 1,000 times high compared to the <italic>in vivo</italic>
concentration (about 1 nmol/l), results of <italic>in vitro</italic> experiments may
merely show a possible mechanism. Further studies are required to explain the <italic>in
vivo</italic> findings by using a lower concentration of angiotensin II <italic>in
vitro</italic> studies.</p></sec><sec><title>Disclosures</title><p>The authors have no con&#x0fb02;ict of interest to declare.</p></sec><sec><title>Funding sources</title><p>This work was supported by the Science and Technology Commission of Shanghai Municipality
(no. 09JC1412300 to Q.D.), and partly by grants from the Ministry of Education, Culture,
Sports, Science, and Technology of Japan (no. 24659385 to X.W.C.; no. 20249045 to
T.M.).</p></sec></sec></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Be&#x00142;towski</surname><given-names>J.</given-names></name></person-group><year>2006</year>. <article-title>Apelin and visfatin: unique &#x0201c;beneficial&#x0201d;
adipokines upregulated in obesity?</article-title><source><italic>Med. Sci.
Monit.</italic></source><volume>12</volume>:
<fpage>RA112</fpage>&#x02013;<lpage>RA119</lpage>. <pub-id pub-id-type="pmid">16733497</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Bogaert</surname><given-names>Y.E.</given-names></name><name><surname>Linas</surname><given-names>S.</given-names></name></person-group><year>2009</year>. <article-title>The role of obesity in the pathogenesis
of hypertension</article-title>. <source><italic>Nat. Clin. Pract.
Nephrol.</italic></source><volume>5</volume>:<fpage>101</fpage>&#x02013;<lpage>111</lpage>.
doi: <pub-id pub-id-type="doi">10.1038/ncpneph1022</pub-id><pub-id pub-id-type="pmid">19107106</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Boucher</surname><given-names>J.</given-names></name><name><surname>Masri</surname><given-names>B.</given-names></name><name><surname>Daviaud</surname><given-names>D.</given-names></name><name><surname>Gesta</surname><given-names>S.</given-names></name><name><surname>Guign&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Mazzucotelli</surname><given-names>A.</given-names></name><name><surname>Castan-Laurell</surname><given-names>I.</given-names></name><name><surname>Tack</surname><given-names>I.</given-names></name><name><surname>Knibiehler</surname><given-names>B.</given-names></name><name><surname>Carp&#x000e9;n&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Audigier</surname><given-names>Y.</given-names></name><name><surname>Saulnier-Blache</surname><given-names>J.S.</given-names></name><name><surname>Valet</surname><given-names>P.</given-names></name></person-group><year>2005</year>. <article-title>Apelin, a newly identified adipokine
up-regulated by insulin and obesity</article-title>.
<source><italic>Endocrinology</italic></source><volume>146</volume>:
<fpage>1764</fpage>&#x02013;<lpage>1771</lpage>.
doi: <pub-id pub-id-type="doi">10.1210/en.2004-1427</pub-id><pub-id pub-id-type="pmid">15677759</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Boustany</surname><given-names>C.M.</given-names></name><name><surname>Bharadwaj</surname><given-names>K.</given-names></name><name><surname>Daugherty</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>D.R.</given-names></name><name><surname>Randall</surname><given-names>D.C.</given-names></name><name><surname>Cassis</surname><given-names>L.A.</given-names></name></person-group><year>2004</year>. <article-title>Activation of the systemic and adipose
renin-angiotensin system in rats with diet-induced obesity and
hypertension</article-title>. <source><italic>Am. J. Physiol. Regul. Integr. Comp.
Physiol.</italic></source><volume>287</volume>:
<fpage>R943</fpage>&#x02013;<lpage>R949</lpage>.
doi: <pub-id pub-id-type="doi">10.1152/ajpregu.00265.2004</pub-id><pub-id pub-id-type="pmid">15191907</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Castan-Laurell</surname><given-names>I.</given-names></name><name><surname>V&#x000ed;tkova</surname><given-names>M.</given-names></name><name><surname>Daviaud</surname><given-names>D.</given-names></name><name><surname>Dray</surname><given-names>C.</given-names></name><name><surname>Kov&#x000e1;cikov&#x000e1;</surname><given-names>M.</given-names></name><name><surname>Kovacova</surname><given-names>Z.</given-names></name><name><surname>Hejnova</surname><given-names>J.</given-names></name><name><surname>Stich</surname><given-names>V.</given-names></name><name><surname>Valet</surname><given-names>P.</given-names></name></person-group><year>2008</year>. <article-title>Effect of hypocaloric diet-induced weight
loss in obese women on plasma apelin and adipose tissue expression of apelin and
APJ</article-title>. <source><italic>Eur. J.
Endocrinol.</italic></source><volume>158</volume>:
<fpage>905</fpage>&#x02013;<lpage>910</lpage>. doi:
<pub-id pub-id-type="doi">10.1530/EJE-08-0039</pub-id><pub-id pub-id-type="pmid">18390990</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Cheng</surname><given-names>X.W.</given-names></name><name><surname>Kuzuya</surname><given-names>M.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Inoue</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Takeshita</surname><given-names>K.</given-names></name><name><surname>Hirashiki</surname><given-names>A.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>G.P.</given-names></name><name><surname>Okumura</surname><given-names>K.</given-names></name><name><surname>Murohara</surname><given-names>T.</given-names></name></person-group><year>2011</year>. <article-title>Inhibition of mineralocorticoid receptor
is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor pitavastatin</article-title>. <source><italic>J.
Hypertens.</italic></source><volume>29</volume>: <fpage>542</fpage>&#x02013;<lpage>552</lpage>.
doi: <pub-id pub-id-type="doi">10.1097/HJH.0b013e328341cedf</pub-id><pub-id pub-id-type="pmid">21119529</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Daviaud</surname><given-names>D.</given-names></name><name><surname>Boucher</surname><given-names>J.</given-names></name><name><surname>Gesta</surname><given-names>S.</given-names></name><name><surname>Dray</surname><given-names>C.</given-names></name><name><surname>Guigne</surname><given-names>C.</given-names></name><name><surname>Quilliot</surname><given-names>D.</given-names></name><name><surname>Ayav</surname><given-names>A.</given-names></name><name><surname>Ziegler</surname><given-names>O.</given-names></name><name><surname>Carpene</surname><given-names>C.</given-names></name><name><surname>Saulnier-Blache</surname><given-names>J.S.</given-names></name><name><surname>Valet</surname><given-names>P.</given-names></name><name><surname>Castan-Laurell</surname><given-names>I.</given-names></name></person-group><year>2006</year>. <article-title>TNF alpha up-regulates apelin expression
in human and mouse adipose tissue</article-title>. <source><italic>FASEB
J.</italic></source><volume>20</volume>: <fpage>1528</fpage>&#x02013;<lpage>1530</lpage>. doi:
<pub-id pub-id-type="doi">10.1096/fj.05-5243fje</pub-id><pub-id pub-id-type="pmid">16723381</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Esler</surname><given-names>M.</given-names></name><name><surname>Straznicky</surname><given-names>N.</given-names></name><name><surname>Eikelis</surname><given-names>N.</given-names></name><name><surname>Masuo</surname><given-names>K.</given-names></name><name><surname>Lambert</surname><given-names>G.</given-names></name><name><surname>Lambert</surname><given-names>E.</given-names></name></person-group><year>2006</year>. <article-title>Mechanisms of sympathetic activation in
obesity-related hypertension</article-title>.
<source><italic>Hypertension</italic></source><volume>48</volume>:
<fpage>787</fpage>&#x02013;<lpage>796</lpage>. doi:
<pub-id pub-id-type="doi">10.1161/01.HYP.0000242642.42177.49</pub-id><pub-id pub-id-type="pmid">17000932</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Fern&#x000e1;ndez-Galilea</surname><given-names>M.</given-names></name><name><surname>P&#x000e9;rez-Matute</surname><given-names>P.</given-names></name><name><surname>Prieto-Hontoria</surname><given-names>P.</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>J.A.</given-names></name><name><surname>Moreno-Aliaga</surname><given-names>M.J.</given-names></name></person-group><year>2011</year>. <article-title>Effects of lipoic acid on apelin in
3T3-L1 adipocytes and in high-fat fed rats</article-title>. <source><italic>J. Physiol.
Biochem.</italic></source><volume>67</volume>: <fpage>479</fpage>&#x02013;<lpage>486</lpage>.
doi: <pub-id pub-id-type="doi">10.1007/s13105-011-0087-1</pub-id><pub-id pub-id-type="pmid">21461750</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Frederich</surname><given-names>R.C.</given-names><suffix>Jr</suffix></name><name><surname>Kahn</surname><given-names>B.B.</given-names></name><name><surname>Peach</surname><given-names>M.J.</given-names></name><name><surname>Flier</surname><given-names>J.S.</given-names></name></person-group><year>1992</year>. <article-title>Tissue-specific nutritional regulation of
angiotensinogen in adipose tissue</article-title>.
<source><italic>Hypertension</italic></source><volume>19</volume>:
<fpage>339</fpage>&#x02013;<lpage>344</lpage>. doi:
<pub-id pub-id-type="doi">10.1161/01.HYP.19.4.339</pub-id><pub-id pub-id-type="pmid">1555865</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Garrison</surname><given-names>R.J.</given-names></name><name><surname>Kannel</surname><given-names>W.B.</given-names></name><name><surname>Stokes</surname><given-names>J.</given-names><suffix>3rd</suffix></name><name><surname>Castelli</surname><given-names>W.P.</given-names></name></person-group><year>1987</year>. <article-title>Incidence and precursors of hypertension
in young adults: the Framingham Offspring Study</article-title>. <source><italic>Prev.
Med.</italic></source><volume>16</volume>: <fpage>235</fpage>&#x02013;<lpage>251</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/0091-7435(87)90087-9</pub-id><pub-id pub-id-type="pmid">3588564</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Gurzu</surname><given-names>B.</given-names></name><name><surname>Petrescu</surname><given-names>B.C.</given-names></name><name><surname>Costuleanu</surname><given-names>M.</given-names></name><name><surname>Petrescu</surname><given-names>G.</given-names></name></person-group><year>2006</year>. <article-title>Interactions between apelin and
angiotensin II on rat portal vein</article-title>. <source><italic>J. Renin Angiotensin
Aldosterone Syst.</italic></source><volume>7</volume>:
<fpage>212</fpage>&#x02013;<lpage>216</lpage>. doi:
<pub-id pub-id-type="doi">10.3317/jraas.2006.040</pub-id><pub-id pub-id-type="pmid">17318790</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Heinonen</surname><given-names>M.V.</given-names></name><name><surname>Purhonen</surname><given-names>A.K.</given-names></name><name><surname>Miettinen</surname><given-names>P.</given-names></name><name><surname>P&#x000e4;&#x000e4;kk&#x000f6;nen</surname><given-names>M.</given-names></name><name><surname>Pirinen</surname><given-names>E.</given-names></name><name><surname>Alhava</surname><given-names>E.</given-names></name><name><surname>Akerman</surname><given-names>K.</given-names></name><name><surname>Herzig</surname><given-names>K.H.</given-names></name></person-group><year>2005</year>. <article-title>Apelin, orexin-A and leptin plasma levels
in morbid obesity and effect of gastric banding</article-title>. <source><italic>Regul.
Pept.</italic></source><volume>130</volume>: <fpage>7</fpage>&#x02013;<lpage>13</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.regpep.2005.05.003</pub-id><pub-id pub-id-type="pmid">15970339</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Ishida</surname><given-names>J.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Hashimoto</surname><given-names>Y.</given-names></name><name><surname>Nishiwaki</surname><given-names>S.</given-names></name><name><surname>Iguchi</surname><given-names>T.</given-names></name><name><surname>Harada</surname><given-names>S.</given-names></name><name><surname>Sugaya</surname><given-names>T.</given-names></name><name><surname>Matsuzaki</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>R.</given-names></name><name><surname>Shiota</surname><given-names>N.</given-names></name><name><surname>Okunishi</surname><given-names>H.</given-names></name><name><surname>Kihara</surname><given-names>M.</given-names></name><name><surname>Umemura</surname><given-names>S.</given-names></name><name><surname>Sugiyama</surname><given-names>F.</given-names></name><name><surname>Yagami</surname><given-names>K.</given-names></name><name><surname>Kasuya</surname><given-names>Y.</given-names></name><name><surname>Mochizuki</surname><given-names>N.</given-names></name><name><surname>Fukamizu</surname><given-names>A.</given-names></name></person-group><year>2004</year>. <article-title>Regulatory roles for APJ, a
seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in
vivo</article-title>. <source><italic>J. Biol.
Chem.</italic></source><volume>279</volume>: <fpage>26274</fpage>&#x02013;<lpage>26279</lpage>.
doi: <pub-id pub-id-type="doi">10.1074/jbc.M404149200</pub-id><pub-id pub-id-type="pmid">15087458</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Iwanaga</surname><given-names>Y.</given-names></name><name><surname>Kihara</surname><given-names>Y.</given-names></name><name><surname>Takenaka</surname><given-names>H.</given-names></name><name><surname>Kita</surname><given-names>T.</given-names></name></person-group><year>2006</year>. <article-title>Down-regulation of cardiac apelin system
in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1
receptor system</article-title>. <source><italic>J. Mol. Cell.
Cardiol.</italic></source><volume>41</volume>: <fpage>798</fpage>&#x02013;<lpage>806</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.07.004</pub-id><pub-id pub-id-type="pmid">16919293</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Japp</surname><given-names>A.G.</given-names></name><name><surname>Cruden</surname><given-names>N.L.</given-names></name><name><surname>Amer</surname><given-names>D.A.</given-names></name><name><surname>Li</surname><given-names>V.K.</given-names></name><name><surname>Goudie</surname><given-names>E.B.</given-names></name><name><surname>Johnston</surname><given-names>N.R.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Neilson</surname><given-names>I.</given-names></name><name><surname>Webb</surname><given-names>D.J.</given-names></name><name><surname>Megson</surname><given-names>I.L.</given-names></name><name><surname>Flapan</surname><given-names>A.D.</given-names></name><name><surname>Newby</surname><given-names>D.E.</given-names></name></person-group><year>2008</year>. <article-title>Vascular effects of apelin in vivo in
man</article-title>. <source><italic>J. Am. Coll.
Cardiol.</italic></source><volume>52</volume>: <fpage>908</fpage>&#x02013;<lpage>913</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2008.06.013</pub-id><pub-id pub-id-type="pmid">18772060</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Japp</surname><given-names>A.G.</given-names></name><name><surname>Cruden</surname><given-names>N.L.</given-names></name><name><surname>Barnes</surname><given-names>G.</given-names></name><name><surname>van Gemeren</surname><given-names>N.</given-names></name><name><surname>Mathews</surname><given-names>J.</given-names></name><name><surname>Adamson</surname><given-names>J.</given-names></name><name><surname>Johnston</surname><given-names>N.R.</given-names></name><name><surname>Denvir</surname><given-names>M.A.</given-names></name><name><surname>Megson</surname><given-names>I.L.</given-names></name><name><surname>Flapan</surname><given-names>A.D.</given-names></name><name><surname>Newby</surname><given-names>D.E.</given-names></name></person-group><year>2010</year>. <article-title>Acute cardiovascular effects of apelin in
humans: potential role in patients with chronic heart failure</article-title>.
<source><italic>Circulation</italic></source><volume>121</volume>:(<issue>16</issue>):
<fpage>1818</fpage>&#x02013;<lpage>1827</lpage>.
doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.911339</pub-id><pub-id pub-id-type="pmid">20385929</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Kanai</surname><given-names>H.</given-names></name><name><surname>Matsuzawa</surname><given-names>Y.</given-names></name><name><surname>Kotani</surname><given-names>K.</given-names></name><name><surname>Keno</surname><given-names>Y.</given-names></name><name><surname>Kobatake</surname><given-names>T.</given-names></name><name><surname>Nagai</surname><given-names>Y.</given-names></name><name><surname>Fujioka</surname><given-names>S.</given-names></name><name><surname>Tokunaga</surname><given-names>K.</given-names></name><name><surname>Tarui</surname><given-names>S.</given-names></name></person-group><year>1990</year>. <article-title>Close correlation of intra-abdominal fat
accumulation to hypertension in obese women</article-title>.
<source><italic>Hypertension</italic></source><volume>16</volume>:
<fpage>484</fpage>&#x02013;<lpage>490</lpage>. doi:
<pub-id pub-id-type="doi">10.1161/01.HYP.16.5.484</pub-id><pub-id pub-id-type="pmid">2228147</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Kelly</surname><given-names>R.B.</given-names></name></person-group><year>1985</year>. <article-title>Pathways of protein secretion in
eukaryotes</article-title>.
<source><italic>Science</italic></source><volume>230</volume>:
<fpage>25</fpage>&#x02013;<lpage>32</lpage>. doi:
<pub-id pub-id-type="doi">10.1126/science.2994224</pub-id><pub-id pub-id-type="pmid">2994224</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Lee</surname><given-names>D.K.</given-names></name><name><surname>George</surname><given-names>S.R.</given-names></name><name><surname>O&#x02019;Dowd</surname><given-names>B.F.</given-names></name></person-group><year>2006</year>. <article-title>Unravelling the roles of the apelin
system: prospective therapeutic applications in heart failure and
obesity</article-title>. <source><italic>Trends Pharmacol.
Sci.</italic></source><volume>27</volume>: <fpage>190</fpage>&#x02013;<lpage>194</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.tips.2006.02.006</pub-id><pub-id pub-id-type="pmid">16530855</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Lorente-Cebri&#x000e1;n</surname><given-names>S.</given-names></name><name><surname>Bustos</surname><given-names>M.</given-names></name><name><surname>Marti</surname><given-names>A.</given-names></name><name><surname>Martinez</surname><given-names>J.A.</given-names></name><name><surname>Moreno-Aliaga</surname><given-names>M.J.</given-names></name></person-group><year>2010</year>. <article-title>Eicosapentaenoic acid up-regulates apelin
secretion and gene expression in 3T3-L1 adipocytes</article-title>. <source><italic>Mol.
Nutr. Food Res.</italic></source><volume>54</volume>:(Suppl 1): <fpage>S104</fpage>&#x02013;<lpage>S111</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mnfr.200900522</pub-id><pub-id pub-id-type="pmid">20352620</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Mathai</surname><given-names>M.L.</given-names></name><name><surname>Naik</surname><given-names>S.</given-names></name><name><surname>Sinclair</surname><given-names>A.J.</given-names></name><name><surname>Weisinger</surname><given-names>H.S.</given-names></name><name><surname>Weisinger</surname><given-names>R.S.</given-names></name></person-group><year>2008</year>. <article-title>Selective reduction in body fat mass and
plasma leptin induced by angiotensin-converting enzyme inhibition in
rats</article-title>. <source><italic>Int. J.
Obes.</italic></source><volume>32</volume>: <fpage>1576</fpage>&#x02013;<lpage>1584</lpage>.
doi: <pub-id pub-id-type="doi">10.1038/ijo.2008.126</pub-id><pub-id pub-id-type="pmid">18698317</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>O&#x02019;Dowd</surname><given-names>B.F.</given-names></name><name><surname>Heiber</surname><given-names>M.</given-names></name><name><surname>Chan</surname><given-names>A.</given-names></name><name><surname>Heng</surname><given-names>H.H.</given-names></name><name><surname>Tsui</surname><given-names>L.C.</given-names></name><name><surname>Kennedy</surname><given-names>J.L.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Petronis</surname><given-names>A.</given-names></name><name><surname>George</surname><given-names>S.R.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name></person-group><year>1993</year>. <article-title>A human gene that shows identity with the
gene encoding the angiotensin receptor is located on chromosome 11</article-title>.
<source><italic>Gene</italic></source><volume>136</volume>:
<fpage>355</fpage>&#x02013;<lpage>360</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/0378-1119(93)90495-O</pub-id><pub-id pub-id-type="pmid">8294032</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Przewlocka-Kosmala</surname><given-names>M.</given-names></name><name><surname>Kotwica</surname><given-names>T.</given-names></name><name><surname>Mysiak</surname><given-names>A.</given-names></name><name><surname>Kosmala</surname><given-names>W.</given-names></name></person-group><year>2011</year>. <article-title>Reduced circulating apelin in essential
hypertension and its association with cardiac dysfunction</article-title>.
<source><italic>J Hypertens.</italic></source><volume>29</volume>:
<fpage>971</fpage>&#x02013;<lpage>979</lpage>. doi:
<pub-id pub-id-type="doi">10.1097/HJH.0b013e328344da76</pub-id><pub-id pub-id-type="pmid">21346619</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Rahmouni</surname><given-names>K.</given-names></name><name><surname>Correia</surname><given-names>M.L.</given-names></name><name><surname>Haynes</surname><given-names>W.G.</given-names></name><name><surname>Mark</surname><given-names>A.L.</given-names></name></person-group><year>2005</year>. <article-title>Obesity-associated hypertension: new
insights into mechanisms</article-title>.
<source><italic>Hypertension</italic></source><volume>45</volume>:
<fpage>9</fpage>&#x02013;<lpage>14</lpage>. doi:
<pub-id pub-id-type="doi">10.1161/01.HYP.0000151325.83008.b4</pub-id><pub-id pub-id-type="pmid">15583075</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Ronkainen</surname><given-names>V.P.</given-names></name><name><surname>Ronkainen</surname><given-names>J.J.</given-names></name><name><surname>H&#x000e4;nninen</surname><given-names>S.L.</given-names></name><name><surname>Leskinen</surname><given-names>H.</given-names></name><name><surname>Ruas</surname><given-names>J.L.</given-names></name><name><surname>Pereira</surname><given-names>T.</given-names></name><name><surname>Poellinger</surname><given-names>L.</given-names></name><name><surname>Vuolteenaho</surname><given-names>O.</given-names></name><name><surname>Tavi</surname><given-names>P.</given-names></name></person-group><year>2007</year>. <article-title>Hypoxia inducible factor regulates the
cardiac expression and secretion of apelin</article-title>. <source><italic>FASEB
J.</italic></source><volume>21</volume>: <fpage>1821</fpage>&#x02013;<lpage>1830</lpage>.
doi: <pub-id pub-id-type="doi">10.1096/fj.06-7294com</pub-id><pub-id pub-id-type="pmid">17341685</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Sironi</surname><given-names>A.M.</given-names></name><name><surname>Gastaldelli</surname><given-names>A.</given-names></name><name><surname>Mari</surname><given-names>A.</given-names></name><name><surname>Ciociaro</surname><given-names>D.</given-names></name><name><surname>Positano</surname><given-names>V.</given-names></name><name><surname>Buzzigoli</surname><given-names>E.</given-names></name><name><surname>Ghione</surname><given-names>S.</given-names></name><name><surname>Turchi</surname><given-names>S.</given-names></name><name><surname>Lombardi</surname><given-names>M.</given-names></name><name><surname>Ferrannini</surname><given-names>E.</given-names></name></person-group><year>2004</year>. <article-title>Visceral fat in hypertension: influence
on insulin resistance and beta-cell function</article-title>.
<source><italic>Hypertension</italic></source><volume>44</volume>:
<fpage>127</fpage>&#x02013;<lpage>133</lpage>. doi:
<pub-id pub-id-type="doi">10.1161/01.HYP.0000137982.10191.0a</pub-id><pub-id pub-id-type="pmid">15262911</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Smith</surname><given-names>A.D.</given-names></name><name><surname>Brands</surname><given-names>M.W.</given-names></name><name><surname>Wang</surname><given-names>M.H.</given-names></name><name><surname>Dorrance</surname><given-names>A.M.</given-names></name></person-group><year>2006</year>. <article-title>Obesity-induced hypertension develops in
young rats independently of the renin-angiotensin-aldosterone system</article-title>.
<source><italic>Exp. Biol. Med. (Maywood)</italic></source><volume>231</volume>:
<fpage>282</fpage>&#x02013;<lpage>287</lpage>. <pub-id pub-id-type="pmid">16514174</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Sonmez</surname><given-names>A.</given-names></name><name><surname>Celebi</surname><given-names>G.</given-names></name><name><surname>Erdem</surname><given-names>G.</given-names></name><name><surname>Tapan</surname><given-names>S.</given-names></name><name><surname>Genc</surname><given-names>H.</given-names></name><name><surname>Tasci</surname><given-names>I.</given-names></name><name><surname>Ercin</surname><given-names>C.N.</given-names></name><name><surname>Dogru</surname><given-names>T.</given-names></name><name><surname>Kilic</surname><given-names>S.</given-names></name><name><surname>Uckaya</surname><given-names>G.</given-names></name><name><surname>Yilmaz</surname><given-names>M.I.</given-names></name><name><surname>Erbil</surname><given-names>M.K.</given-names></name><name><surname>Kutlu</surname><given-names>M.</given-names></name></person-group><year>2010</year>. <article-title>Plasma apelin and ADMA Levels in patients
with essential hypertension</article-title>. <source><italic>Clin. Exp.
Hypertens.</italic></source><volume>32</volume>:
<fpage>179</fpage>&#x02013;<lpage>183</lpage>. doi:
<pub-id pub-id-type="doi">10.3109/10641960903254505</pub-id><pub-id pub-id-type="pmid">20504125</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name><surname>Tatemoto</surname><given-names>K.</given-names></name><name><surname>Hosoya</surname><given-names>M.</given-names></name><name><surname>Habata</surname><given-names>Y.</given-names></name><name><surname>Fujii</surname><given-names>R.</given-names></name><name><surname>Kakegawa</surname><given-names>T.</given-names></name><name><surname>Zou</surname><given-names>M.X.</given-names></name><name><surname>Kawamata</surname><given-names>Y.</given-names></name><name><surname>Fukusumi</surname><given-names>S.</given-names></name><name><surname>Hinuma</surname><given-names>S.</given-names></name><name><surname>Kitada</surname><given-names>C.</given-names></name><name><surname>Kurokawa</surname><given-names>T.</given-names></name><name><surname>Onda</surname><given-names>H.</given-names></name><name><surname>Fujino</surname><given-names>M.</given-names></name></person-group><year>1998</year>. <article-title>Isolation and characterization of a novel
endogenous peptide ligand for the human APJ receptor</article-title>.
<source><italic>Biochem. Biophys. Res. Commun.</italic></source><volume>251</volume>:
<fpage>471</fpage>&#x02013;<lpage>476</lpage>. doi:
<pub-id pub-id-type="doi">10.1006/bbrc.1998.9489</pub-id><pub-id pub-id-type="pmid">9792798</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Tatemoto</surname><given-names>K.</given-names></name><name><surname>Takayama</surname><given-names>K.</given-names></name><name><surname>Zou</surname><given-names>M.X.</given-names></name><name><surname>Kumaki</surname><given-names>I.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Kumano</surname><given-names>K.</given-names></name><name><surname>Fujimiya</surname><given-names>M.</given-names></name></person-group><year>2001</year>. <article-title>The novel peptide apelin lowers blood
pressure via a nitric oxide-dependent mechanism</article-title>. <source><italic>Regul.
Pept.</italic></source><volume>99</volume>: <fpage>87</fpage>&#x02013;<lpage>92</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/S0167-0115(01)00236-1</pub-id><pub-id pub-id-type="pmid">11384769</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Than</surname><given-names>A.</given-names></name><name><surname>Tee</surname><given-names>W.T.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name></person-group><year>2012</year>. <article-title>Apelin secretion and expression of apelin
receptors in 3T3-L1 adipocytes are differentially regulated by angiotensin type 1 and
type 2 receptors</article-title>. <source><italic>Mol. Cell
Endocrinol.</italic></source><volume>351</volume>:
<fpage>296</fpage>&#x02013;<lpage>305</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.mce.2012.01.005</pub-id><pub-id pub-id-type="pmid">22249006</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group><name><surname>Turban</surname><given-names>S.</given-names></name><name><surname>Hainault</surname><given-names>I.</given-names></name><name><surname>Truccolo</surname><given-names>J.</given-names></name><name><surname>Andre</surname><given-names>J.</given-names></name><name><surname>Ferre</surname><given-names>P.</given-names></name><name><surname>Quignard-Boulange</surname><given-names>A.</given-names></name><name><surname>Guerre-Millo</surname><given-names>M.</given-names></name></person-group><year>2002</year>. <article-title>Specific increase in leptin production in
obese (fa/fa) rat adipose cells</article-title>. <source><italic>Biochem.
J.</italic></source><volume>362</volume>:(<issue>Pt 1</issue>):
<fpage>113</fpage>&#x02013;<lpage>118</lpage>. doi:
<pub-id pub-id-type="doi">10.1042/0264-6021:3620113</pub-id><pub-id pub-id-type="pmid">11829746</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group><name><surname>Wakabayashi</surname><given-names>I.</given-names></name></person-group><year>2012</year>. <article-title>Stronger associations of obesity with
prehypertension and hypertension in young women than in young men</article-title>.
<source><italic>J. Hypertens.</italic></source><volume>30</volume>:
<fpage>1423</fpage>&#x02013;<lpage>1429</lpage>.
doi: <pub-id pub-id-type="doi">10.1097/HJH.0b013e3283544881</pub-id><pub-id pub-id-type="pmid">22573123</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Tatemoto</surname><given-names>K.</given-names></name></person-group><year>2005</year>. <article-title>Regulation of apelin mRNA expression by
insulin and glucocorticoids in mouse 3T3-L1 adipocytes</article-title>.
<source><italic>Regul. Pept.</italic></source><volume>132</volume>:
<fpage>27</fpage>&#x02013;<lpage>32</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.regpep.2005.08.003</pub-id><pub-id pub-id-type="pmid">16137778</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group><name><surname>Weisinger</surname><given-names>R.S.</given-names></name><name><surname>Stanley</surname><given-names>T.K.</given-names></name><name><surname>Begg</surname><given-names>D.P.</given-names></name><name><surname>Weisinger</surname><given-names>H.S.</given-names></name><name><surname>Spark</surname><given-names>K.J.</given-names></name><name><surname>Jois</surname><given-names>M.</given-names></name></person-group><year>2009</year>. <article-title>Angiotensin converting enzyme inhibition
lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high
fat diet</article-title>. <source><italic>Physiol.
Behav.</italic></source><volume>98</volume>: <fpage>192</fpage>&#x02013;<lpage>197</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.physbeh.2009.05.009</pub-id><pub-id pub-id-type="pmid">19465040</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Boyle</surname><given-names>D.</given-names></name><name><surname>Sanford</surname><given-names>D.</given-names></name><name><surname>Scherer</surname><given-names>P.E.</given-names></name><name><surname>Pessin</surname><given-names>J.E.</given-names></name><name><surname>Mora</surname><given-names>S.</given-names></name></person-group><year>2006</year>. <article-title>Intracellular trafficking and secretion
of adiponectin is dependent on GGA-coated vesicles</article-title>. <source><italic>J.
Biol. Chem.</italic></source><volume>281</volume>:
<fpage>7253</fpage>&#x02013;<lpage>7259</lpage>.
doi: <pub-id pub-id-type="doi">10.1074/jbc.M511313200</pub-id><pub-id pub-id-type="pmid">16407204</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Than</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Goh</surname><given-names>K.H.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name></person-group><year>2010</year>. <article-title>Vesicular storage, vesicle trafficking,
and secretion of leptin and resistin: the similarities, differences, and
interplays</article-title>. <source><italic>J.
Endocrinol.</italic></source><volume>206</volume>: <fpage>27</fpage>&#x02013;<lpage>36</lpage>.
doi: <pub-id pub-id-type="doi">10.1677/JOE-10-0090</pub-id><pub-id pub-id-type="pmid">20392813</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>C.X.</given-names></name><name><surname>Qi</surname><given-names>Y.F.</given-names></name><name><surname>Lou</surname><given-names>L.X.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.K.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name></person-group><year>2006</year>. <article-title>Exercise training promotes expression of
apelin and APJ of cardiovascular tissues in spontaneously hypertensive
rats</article-title>. <source><italic>Life Sci.</italic></source><volume>79</volume>:
<fpage>1153</fpage>&#x02013;<lpage>1159</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2006.03.040</pub-id><pub-id pub-id-type="pmid">16674982</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group><name><surname>Zhong</surname><given-names>J.C.</given-names></name><name><surname>Huang</surname><given-names>D.Y.</given-names></name><name><surname>Liu</surname><given-names>G.F.</given-names></name><name><surname>Jin</surname><given-names>H.Y.</given-names></name><name><surname>Yang</surname><given-names>Y.M.</given-names></name><name><surname>Li</surname><given-names>Y.F.</given-names></name><name><surname>Song</surname><given-names>X.H.</given-names></name><name><surname>Du</surname><given-names>K.</given-names></name></person-group><year>2005</year>. <article-title>Effects of all-trans retinoic acid on
orphan receptor APJ signaling in spontaneously hypertensive rats</article-title>.
<source><italic>Cardiovasc. Res.</italic></source><volume>65</volume>:
<fpage>743</fpage>&#x02013;<lpage>750</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.cardiores.2004.10.020</pub-id><pub-id pub-id-type="pmid">15664402</pub-id></mixed-citation></ref></ref-list></back></article>